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Lipopolysaccharide (LPS)-Binding Protein in Human Serum Determines the
Tumor Necrosis Factor Response of Monocytes to LPS
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Lipopolysaccharide (LPS)-binding protein (LBP) and CD14 represent key elements in mono-
cyte activation by LPS. The mean concentration of LBP was 18.1 Ilg/mL in normal serum and
40-60 J,Lg/mL in serum of patients with septic shock, independent of the fact that patients had
gram-negative or other infections. Ten percent normal serum presented large concentrations of
LPS (in the microgram range) to monocytes. Only when diluted 1:100 was LBP in plasma a
limiting factor for monocyte activation, as measured by tumor necrosis factor (TNF) release.
When LBP was depleted from serum with anti-LBP antibodies, the resulting serum did not
support TNF release of monocytes upon LPS challenge. In conclusion, monocyte activation
resulting in TNF secretion was related to LBP, which is abundantly present in normal serum, and
elevated two to three times in patients with septic shock.
Evidence from in vitro studies implicates serum lipopoly-
saccharide (LPS)-binding protein (LBP) and monocyte
CD 14 as major factors contributing to the LPS-induced acti-
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vation of monocytes [1-4]. However, it is not clear whether
the interaction ofLPS with LBP and CD 14 is the major mech-
anism in triggering monocytes or whether other mechanisms
ofLPS recognition involving other monocyte receptors [5] or
other serum mediators [6] could also be operational. At low
concentrations of LPS, tumor necrosis factor (TNF) release
by human monocytes appeared to be mostly dependent
upon the presence ofLBP or septin and CD 14 [1-3,6]. How-
ever, the presence of CD 14 and LBP as a prerequisite for
LPS-induced monocyte activation has been questioned. In-
deed, secretion of TNF and interleukin-I (IL-l) has been
observed in the absence of LBP and in CD 14-deficient pa-
tients [4], implicating the participation of receptors other
than CD 14. Using sera from normal donors and patients
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with septic shock, we investigated the process of monocyte
activation leading to TNF release by human monocytes with
respect to CD 14 and LBP, examining the relationships be-
tween the concentration of serum and the presence ofCD 14.
Materials and Methods
Blood. Serum was collected in endotoxin-free tu bes at study
entry and at day 10 from 77 patients with septic shock [7]. In
addition, fresh and outdated samples from 60 normal blood do-
nors were used. Serum was stored at -70°(' and underwent up
to two freeze-thaw cycles before being assayed.
Materials. 0 I I I LPS, unlabeled or labeled with fluorescein
isothiocyanate (FITC) was from Sigma (St. Louis), and anti-
CD 14 monoclonal antibody (MAb) MY 4 was from Coulter Im-
munology (Luton, UK). Human recombinant LBP (rh-LBP)
was a gift ofR. J. Ulevitch (Scripps Clinic).
Blood from normal donors was collected in endotoxin-free
heparin to prepare peripheral blood mononuclear cells (PBMC)
by centrifugation over Ficoll-Paque (Pharrnacia, Uppsala, Swe-
den).
LBP depletion. LBP was depleted from serum using IgG
from a goat immunized with rh-LBP [8]. Serum (I mL) was
treated overnight with 10 mg of protein-G goat IgG or, as a
control, normal goat immune IgG. Immune complexes were
eliminated by centrifugation at 13,000 g for 10 min at 4°C.
Binding assay ofFITC-LPS to monocvtes. PBM(' (106 ) were
incubated with I Jlg/mL FITC-LPS in I mL ofmedium enriched
with human serum (1.0% or 0.1 %) or with 4%albumin. Binding
of FITC-LPS to monocytes was assessed by flow cytometry [3].
RIA and ELISA for measuring plasma levels ofLBP. LBP was
measured by a sandwich RIA using monophosphoryl lipid A
(Ribi Chemicals, Hamilton, MT) as the solid phase and 12sl_la_
beled IgG directed against rh-LBP to detect captured LBP [9].
LBP was also measured by ELISA made up of two MAbs to LBP
[10].
TNF assays. PBMC (0.5 X 106 ) in 200 JlL of medium
enriched with 1.0% and O. I% serum were stimulated with unla-
beled LPS at a concentration of I ng/mL. Supernatants were
collected for TNF measurements after 4 h of culture at 37°C
using a bioassay set up with WEHI cells [11].
Statistical analysis. Measurements ofLBP were presented as
mean ± SO. Differences between groups were estimated using a
two-tailed Student's t test. Regression analysis was estimated
according to the transformation of Fisher [12].
Results
At entry, the mean concentration of LBP was 58.1 ± 13.7
Jig/mL in patients who survived gram-negative shock and
52.0 ± 7.6 Jig/mL in patients who died. In patients with
septic shock from causes other than gram-negative bacteria,
the concentrations ofLBP at entry were 52.0 ± 3.9 Jig/mL in
patients who survived and 41.2 ± 12.1 Jig/mL in patients
who died. These values were statistically similar among
groups. Furthermore, these LBP concentrations were in the
same range for samples obtained 10 days after the onset of
shock: 54.3 ± 14.6 Jig/mL in patients with gram-negative
shock; 46.8 ± 12.7 Jig/mL in patients with septic shock from
other causes. By statistical analysis, no differences were ob-
served when LBP values were correlated with outcome or
with a specific type of infection. In addition, neither the ini-
tial level nor the level 10 days after the onset of the disease
had a predictive value for survival in individual patients
(data not shown).
Correlation ofLBP levels measured by RIA and byflowcyto-
metric assay. We previously reported that LBP could be
measured in plasma by using its ability to present FITC-LPS
to CD 14 on monocytes [3, 9]. Serum-mediated binding of
FITC-LPS to monocytes was found to be correlated with
LBP concentrations measured by RIA for both normal do-
nors (r = .87, P < 10-3) and for patients with septic shock at
study entry (r = .91, P < 10-3 ) . Repeated freeze-thaw cycles
of the samples or use of fresh versus outdated plasma did not
modify LBP measurements (data not shown).
We pooled normal donor sera (3-6 serum samples/pool)
with high (pool A) and low (pool B) LBP activity. By RIA
and ELISA, respectively, we measured 39 ± 3 and 41 ± 16
Jig/mL LBP in pool A and 10.5 ± 2.1 and 11 ± 5 Jig/mL LBP
in pool B.
Effect ofLBP depletion on the flow cytometric assay. We
confirmed that the flow cytometric assay actually measured
LBP by depletion experiments (table 1). Treatment of serum
with anti-LBP but not with control IgG suppressed the
serum-mediated binding of FITC-LPS to monocytes to a
level similar to that observed in monocytes preincubated
Table 1. Effect of LBP depletion and supplementation on serum-
mediated binding of fluorescein isothiocyanate-Iabeled LPS to
monocytes as assessed by flow cytometry.
Fluorescence units
NOTE: rh = recombinant human.
* High LBP.
t Low LBP.
Determination of LBP concentrations. Patients in septic
shock had higher LBP concentrations in serum than did nor-
mal volunteers, as measured by RIA. The mean concentra-
tion of LBP was 18. I ± 4.0 Jig/mL in normal sera, 54.1 ±
10.2 Jig/mL in sera collected at entry from patients with
gram-negative shock, and 45.4 ± 8.7 Jlg/mL in sera of pa-
tien ts with shock caused by other organisms or with no micro-
biologic documentation. LBP levels in these 2 groups of pa-
tients were higher than levels in normal donors (P < 10-s).
Serum
10%
+ control IgG
+ anti-rh-LBP IgG
+ anti-rh-LBP IgG + 10 foLg rh-LBP
Control (4% albumin)
Pool A* Pool Bt
47.1 27.2
37.2 28.0
2.9 2.7
66.9 55.7
3.1 2.8
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with anti-CD 14 MAb. The specificity of the immunodeple-
tion experiments was assessed by adding back rh-LBP, which
restored FITC-LPS binding to monocytes.
Effects of variable LBP concentrations on the binding 10
monocvtes. We previously showed that the binding of
FITC-LPS to monocytes can be inhibited by preincubation
of serum with nonfluorescent LPS [3]; therefore, we preincu-
bated 10% serum with increasing concentrations ofnonfluo-
rescent LPS for 30 min before adding PBMC with FITC-LPS
for an additional 30 min and assessing binding ofFITC-LPS
to monocytes by flow cytometry. When 50-75 ~g/mL LPS
was first added to 10% serum, there was still partial binding
of the 1-~g/mL fluorescent probe to monocytes, suggesting
an absence of total saturation of LBP in the preincubation
period. Only when using I 00 ~g/mL unlabeled LPS was
FITC-LPS binding suppressed.
Using this protocol, the ICso (i.e., the concentration of
unlabeled LPS that reduced by 50% the maximal binding of
FITC-LPS) was related to the concentration of LBP. The
ICso was threefold higher in pool A (12.3 ± 1.5 ~g/mL) than
in pool B (4.3 ± 0.8 ~g/mL; mean ± so of 3 experiments).
These experiments showed that FITC-LPS binding was re-
lated to the concentration ofLBP. In other experiments (not
shown), the limiting factor for LPS binding was actually
LBP, not CD 14. Indeed, monocytes first incubated with 100
~g/mL LPS did not bind FITC-LPS. However, the same
monocytes were able to bind FITC-LPS if fresh LBP was
subsequently added, but this binding was suppressed by
CD 14 blockade.
Effects ofLBP on TNF release by tnonocytes. Since bind-
ing experiments showed that the amount of LPS bound to
monocytes was dependent upon the amount of LBP present
in serum, we analyzed the involvement ofLBP in the indue-
Table 2. Effect ofserum dilution and LBP blockade on binding of
fluorescein isothiocyanate-Iabeled LPS to monocytes and on tu-
mor necrosis factor (TNF) release by peripheral blood mononu-
clear cells upon LPS challenge.
LPS binding
(FU)* TNF release (pg/mL)t
PBMC
incubation conditions Pool A Pool B Pool A Pool B
Experiment I
If+ pool ND ND 910 ± 120 430 ± 170
+ control IgG NO ND 920 ± 150 420 ± 130
+ anti-LBP IgG ND ND 20 ± 25 30 ± 25
Experiment 2
I(t pool 38 17 800 ± 220 380 ± 35
O.lfX pool 15 4 360 ± 140 70 ± 30
NOTE. Pool A = high LBP; Pool B = low LBP; ND = not done.
* Binding was 2.5 fluorescence units (FU) on cells incubated with control
albumin. Assessed by flow cytometry.
t Stimulus was I ng/mL LPS. No TNF was detected by bioassay when
cells were incubated in medium alone.
tion of TNF release by monocytes upon LPS challenge. As
shown in table 2. the presence of LBP was a prerequisite for
TNF secretion, since treatment of serum with anti-LBP IgG
(but not control IgG) suppressed TNF release. The concen-
tration ofLBP also determined the response when serum was
highly diluted: 0.1 % pool B was less efficient than 0.1 % pool
A in its ability to present FITC-LPS to monocytes and to
sustain a TNF response.
Discussion
The data support the view that LBP is a key serum compo-
nent in the process of monocyte activation by LPS. The de-
pletion of LBP from sera suppressed both the serum-me-
diated LPS binding and the TNF production of monocytes
stimulated with LPS. In the activation experiments. we used
LPS concentrations that are usually found in septic shock
patients (nanogram per liter range) [13]. The role played by
septin, which could bind LPS and which is inhibited by
CD14 blockade [6], appeared not to be directly linked to
TNF production in our experiments, since the mere deple-
tion of LBP from serum efficiently suppressed TNF produc-
tion. Furthermore, addition of exogenous rh-LBP in the
serum depleted from LBP restored LPS binding to mono-
cytes. Thus. activation of monocytes by low LPS concentra-
tions through pathways not related to CD 14 and LBP ap-
peared to be of minor importance.
The data showed that very high quantities of LPS can be
presented to monocytes through LBP. In 10% serum, prein-
cubation with 4-12 ~g/mL LPS was required to diminish by
half the maximal subsequent LBP-mediated binding of LPS
to monocytes. This demonstrated that LBP in normal plasma
was able to enhance LPS binding to monocytes in concentra-
tions far above those found in patients presenting with
shock. Furthermore, the factor that limited the binding of
LPS to monocytes was the presence of LBP not CD 14. In
experiments in which monocytes were preincubated with
very large concentrations of LPS, followed by washing and
incubation with fresh LBP. the LBP could restore LPS bind-
ing to monocytes.
The mean concentration ofLBP was 18.1 ~g/mL in serum
ofnormal donors. This concentration was similar to that pre-
viously measured in plasma (17.8 ~g/mL) [9]. Both ELISA
and RIA gave similar values of LBP in serum. Our data also
showed that the ability of LBP to present LPS-LBP com-
plexes to monocytes could be estimated by flow cytometry
[9). LBP levels were higher in blood of septic patients, and
the response was not specifically related to gram-negative
infection. LBP levels did not have a predictive value for sur-
vival in individual patients. and LBP levels are likely to repre-
sent a measure of the acute-phase response in these patients.
Normal serum contains 10 to 100 times more LBP than
the level needed for monocyte activation. During physio-
logic conditions and even more during the acute-phase reac-
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tion, LBP is not a limiting factor for LPS-induced monocyte
activation. Our data showed that LBP was the only factor
present in serum responsible for TNF release of monocytes
upon LPS stimulation.
On the other hand, serum contains many factors that can
interfere with the presentation ofLPS to monocytes, includ-
ing LPS antibodies and lipoproteins [14, 15], and with mono-
cyte activation, such as antiinflammatory cytokines, includ-
ing IL-l 0, IL-13 and IL-4. Different levels of these factors
could partially explain the variability of the response of se-
creted TNF, depending on the donors. However, the present
data suggest that when LBP was limiting in highly diluted
serum, the serum pool with low LBP concentration was less
active than the pool with high LBP concentration in its abil-
ity both to present LPS and to sustain TNF release. Thus,
this observation and the fact that LBP blockade suppressed
TNF release suggest that the level ofLBP was a major factor,
although the involvement of other factors could not be ex-
cluded. Measurements of LBP in biologic and tissue fluids
will help determine if LBP is present in sufficient concentra-
tion to activate tissue monocytes in the presence of LPS or
gram-negative bacteria.
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